maravai lifesciences holdings glp-1 receptor agonist medications Harnessing Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon GLP-1 Pipeline Update: February 2025

Key mechanisms of action include: Appetite suppression through central nervous system pathways that regulate hunger and satiety Delayed gastric emptying , which prolongs the sensation of fullness after eating Improved glucose metabolism and insulin sensitivity, which may benefit individuals with obesity-related metabolic complications GIP receptor antagonism , which may influence fat metabolism and energy storage The once-monthly dosing schedule is achieved through the extended half-life of the antibodypeptide construct, which may improve convenience and adherence compared with current weekly injectable obesity treatments

Jensen EP, Mller S, Hviid AV, Veedfald S, Holst JJ, Pedersen J, rskov C, Sorensen CM

The Government Accountability Office (GAO) released a report in 2023 examining how the patent and regulatory system for drug-device combinations may be delaying generic competition

These results give us a direction that GLP-1RAs, currently used for diabetes, may be an alternative drug for the treatment of osteoporosis

There are several reasons your doctor might recommend you avoid GLP-1s

GLP-1 medicines started with injectable GLP-1RAs, then moved to oral peptides, and now co-agonists